Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction.
Bivalirudin is a direct thrombin inhibitor that seems to be a promising anticoagulation treatment in patient with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). We discuss several issues that were raised from the use of Bivalirudin during primary PCI.
Koutouzis
Michael
M
Albertsson
Per
P
D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D006629:Hirudins; D006801:Humans; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D015203:Reproducibility of Results; D012107:Research Design
D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C074619:bivalirudin